




RealRate

PHARMACEUTICAL 2019

Neoleukin Therapeutics Inc.
Rank 160 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2019

Neoleukin Therapeutics Inc. Rank 160 of 371



The relative strengths and weaknesses of Neoleukin Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Neoleukin Therapeutics Inc. compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 120% points. The greatest weakness of Neoleukin Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 165% points.

The company's Economic Capital Ratio, given in the ranking table, is -117%, being 215% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	77,165
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,627
Liabilities, Non-Current	319
Other Assets	53
Other Compr. Net Income	70
Other Expenses	0
Other Liabilities	0
Other Net Income	1,039
Property and Equipment	400
Research and Development	41,789
Revenues	25,000
Selling, General and Administrative Expense	15,835

Output Variable	Value in 1000 USD
Assets	77,618
Liabilities	4,946
Expenses	57,624
Stockholders Equity	72,672
Net Income	-31,585
Comprehensive Net Income	-31,550
Economic Capital Ratio	-117%

